Nevisense Go, a portable, non-invasive tool that uses electrical impedance spectroscopy measurements for skin barrier assessment, will be studied in clinical practice at hospitals in Switzerland.
WHY IT MATTERS
With 20% of children developing atopic dermatitis, SciBase, developer of the AI…
Source: Healthcareitnews.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
